interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Olaparib

Generic competition · all medicines · read 12 November 2026

Is there a generic of Olaparib, and who makes it?

Olaparib appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Olaparib2 dosage-form groups in the Orange Book
0generic makers listed
  1. Olaparib appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Lynparza. No generic is listed as marketed.

201520202025203020352040204501brand 2017data datePatent 8143241 listed to expire 12 August 2027Patent 8071579 listed to expire 12 August 2027Patent 7449464 listed to expire 8 September 2027Patent 11633396 listed to expire 7 October 2029Patent 12048695 listed to expire 7 October 2029Patent 12178816 listed to expire 7 October 2029Patent 12144810 listed to expire 7 October 2029Patent 11975001 listed to expire 7 October 2029Patent 8475842 listed to expire 31 December 2029Patent 8859562 listed to expire 4 August 2031Patent 11970530 listed to expire 25 October 2041Exclusivity ODE-283 to 27 December 2026Exclusivity ODE-306 to 8 May 2027
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 27 December 2026Exclusivity ODE-283 Lynparza
  • 8 May 2027Exclusivity ODE-306 Lynparza
  • 12 August 2027Patent 8143241
  • 12 August 2027Patent 8071579
  • 8 September 2027Patent 7449464 drug substance
  • 7 October 2029Patent 11633396 drug product
  • 7 October 2029Patent 12048695 drug product
  • 7 October 2029Patent 12178816 drug product
  • 7 October 2029Patent 12144810 drug product
  • 7 October 2029Patent 11975001 drug product

3 more patents are listed.

Capsule, Oral

Nothing listed as marketed

Every brand product here is listed as discontinued. No generic is listed as marketed.

2010201520202025203001brand 2014data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.